Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Dec;51(12):1318–1321. doi: 10.1136/ard.51.12.1318

Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.

E F Morand 1, P I McCloud 1, G O Littlejohn 1
PMCID: PMC1004927  PMID: 1485814

Abstract

BACKGROUND: Hydroxychloroquine is used for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Long term studies have shown a high rate of termination of hydroxychloroquine treatment in patients with RA. Although it has been shown that discontinuation of treatment with hydroxychloroquine is associated with exacerbation of SLE, long term maintenance rates of treatment with hydroxychloroquine in patients with SLE have not been investigated. METHODS: Hydroxychloroquine use in patients with RA and SLE in a group of patients in a single community rheumatology practice was studied. Information was drawn from a computer drug use database containing details of the beginning and end of treatment. Data were analysed using life table methods. RESULTS: Four hundred and three treatment episodes (366 patients with RA, 37 patients with SLE) were observed over eight years. In patients with RA, the cumulative probability of discontinuing treatment was 37% at 12 months and 54% at 24 months. In contrast, hydroxychloroquine treatment of patients with SLE continued over significantly longer periods of time (p < 0.001); the discontinuation probabilities at 12 and 24 months were 8 and 24% respectively. Treatment terminations were predominantly for inefficacy; terminations for toxicity were limited to the first 19 months of treatment. No ocular toxicity was observed. CONCLUSIONS: Treatment of patients with RA in a community rheumatology practice with hydroxychloroquine has a low probability of long term continuation, mostly because of inadequate control of disease manifestations rather than toxicity. In patients with SLE, treatment with hydroxychloroquine has a significantly higher probability of long term continuation.

Full text

PDF
1318

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams E. M., Yocum D. E., Bell C. L. Hydroxychloroquine in the treatment of rheumatoid arthritis. Am J Med. 1983 Aug;75(2):321–326. doi: 10.1016/0002-9343(83)91211-1. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Bellamy N., Brooks P. M. Current practice in antimalarial drug prescribing in rheumatoid arthritis. J Rheumatol. 1986 Jun;13(3):551–555. [PubMed] [Google Scholar]
  4. Bunch T. W., O'Duffy J. D. Disease-modifying drugs for progressive rheumatoid arthritis. Mayo Clin Proc. 1980 Mar;55(3):161–179. [PubMed] [Google Scholar]
  5. Bunch T. W., O'Duffy J. D., Tompkins R. B., O'Fallon W. M. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum. 1984 Mar;27(3):267–276. doi: 10.1002/art.1780270304. [DOI] [PubMed] [Google Scholar]
  6. Dubois E. L. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum. 1978 Aug;8(1):33–51. doi: 10.1016/0049-0172(78)90033-1. [DOI] [PubMed] [Google Scholar]
  7. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med. 1988 Oct 14;85(4A):23–29. doi: 10.1016/0002-9343(88)90358-0. [DOI] [PubMed] [Google Scholar]
  8. FREEDMAN A. Chloroquine and rheumatoid arthritis; a short-term controlled trial. Ann Rheum Dis. 1956 Sep;15(3):251–257. doi: 10.1136/ard.15.3.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. FREEDMAN A., STEINBERG V. L. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis. 1960 Sep;19:243–250. doi: 10.1136/ard.19.3.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Felson D. T., Anderson J. J., Meenan R. F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990 Oct;33(10):1449–1461. doi: 10.1002/art.1780331001. [DOI] [PubMed] [Google Scholar]
  11. Felson D. T. Clinical trials in rheumatoid arthritis under attack: are practice based observational studies the answer? J Rheumatol. 1991 Jul;18(7):951–953. [PubMed] [Google Scholar]
  12. Hawley D. J., Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol. 1991 Jul;18(7):1008–1014. [PubMed] [Google Scholar]
  13. Husain Z., Runge L. A. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole. J Rheumatol. 1980 Nov-Dec;7(6):825–830. [PubMed] [Google Scholar]
  14. Lockshin M. D. Therapy for systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):189–191. doi: 10.1056/NEJM199101173240309. [DOI] [PubMed] [Google Scholar]
  15. MULLINS J. F., WATTS F. L., WILSON C. J. Plaquenil in the treatment of lupus erythematosus. J Am Med Assoc. 1956 Jun 30;161(9):879–881. doi: 10.1001/jama.1956.62970090020017k. [DOI] [PubMed] [Google Scholar]
  16. Maksymowych W., Russell A. S. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum. 1987 Feb;16(3):206–221. doi: 10.1016/0049-0172(87)90023-0. [DOI] [PubMed] [Google Scholar]
  17. McCarty D. J. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J Rheumatol. 1990 Sep;17(9):1115–1118. [PubMed] [Google Scholar]
  18. Morand E. F., McCloud P. I., Littlejohn G. O. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol. 1992 May;19(5):704–708. [PubMed] [Google Scholar]
  19. Nuver-Zwart I. H., van Riel P. L., van de Putte L. B., Gribnau F. W. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis. 1989 May;48(5):389–395. doi: 10.1136/ard.48.5.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Paulus H. E. Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs. Am J Med. 1988 Oct 14;85(4A):45–52. doi: 10.1016/0002-9343(88)90362-2. [DOI] [PubMed] [Google Scholar]
  21. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  22. Richter J. A., Runge L. A., Pinals R. S., Oates R. P. Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis. J Rheumatol. 1980 Mar-Apr;7(2):153–159. [PubMed] [Google Scholar]
  23. Rudnicki R. D., Gresham G. E., Rothfield N. F. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol. 1975 Sep;2(3):323–330. [PubMed] [Google Scholar]
  24. Runge L. A. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med. 1983 Jul 18;75(1A):52–56. doi: 10.1016/0002-9343(83)91271-8. [DOI] [PubMed] [Google Scholar]
  25. Rynes R. I. Hydroxychloroquine treatment of rheumatoid arthritis. Am J Med. 1988 Oct 14;85(4A):18–22. doi: 10.1016/0002-9343(88)90357-9. [DOI] [PubMed] [Google Scholar]
  26. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  27. Tett S., Cutler D., Day R. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol. 1990 Dec;4(3):467–489. doi: 10.1016/s0950-3579(05)80004-4. [DOI] [PubMed] [Google Scholar]
  28. Wolfe F., Hawley D. J., Cathey M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990 Aug;17(8):994–1002. [PubMed] [Google Scholar]
  29. van Saase J., Vandenbroucke J., Valkenburg H., Boersma J., Cats A., Festen J., Hartman A., Huber-Bruning O., Rasker J., Weber J. Changing pattern of drug use in relation to disease duration of rheumatoid arthritis. J Rheumatol. 1987 Jun;14(3):476–478. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES